Aquilon Pharma Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.63M

  • Investors
  • 5

Aquilon Pharma General Information

Description

Developer of pharmaceutical drugs designed to offer the treatment of pulmonary diseases. The company focuses on the development of drugs for the treatment of respiratory disorders and enhances both the lung deposition and the pharmacology of existing drugs for asthma and chronic obstructive pulmonary disease, enabling patients to get efficient inhalation drugs for respiratory problems.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Corporate Office
  • 59 Quai de la Boverie
  • Walloon Region
  • 4020 Liege
  • Belgium
+32 04 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aquilon Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 17-Feb-2023 $1.63M 00.00 00.000 Completed Generating Revenue
4. Later Stage VC Cancelled Generating Revenue
3. Later Stage VC 12-Dec-2018 00.00 00.000 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Oct-2015 $388K $388K 00000 Completed Generating Revenue
1. Accelerator/Incubator 14-Nov-2011 Completed Generating Revenue
To view Aquilon Pharma’s complete valuation and funding history, request access »

Aquilon Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
E Shares 0,000 000.00 000.00 00 000.00 0.000
D Shares 00,000 000.00 000.00 00 000.00 0.000
C Shares 0,000 000.00 000.00 00 000.00 0.00
B Shares 0,000 000.00 000.00 00 000.00 0.000
A Shares 0,000 000.00 000.00 00 000.00 0.000
Ordinary 31,942 $49.88 $49.88 1x $49.88 21.17%
Ordinary 345 $1080.92 $1080.92 1x $1080.92 0.23%
To view Aquilon Pharma’s complete cap table history, request access »

Aquilon Pharma Patents

Aquilon Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4003320-B1 Microparticles with golf ball depressions for use in the treatment and prevention of pulmonary diseases Active 10-Sep-2019 0000000000
EP-4003320-A1 Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases Active 10-Sep-2019 0000000000
CA-3150551-A1 Golf ball-like microparticles for use in the treatment and prevention of pulmonary diseases Active 10-Sep-2019 0000000000
EP-4190321-A1 Microparticles with golf ball depressions for use in the treatment and prevention of pulmonary diseases Pending 10-Sep-2019 0000000000 0
ES-2942901-T3 Microparticles with golf ball-shaped depressions for use in the treatment and prevention of lung diseases Active 10-Sep-2019 A61K9/1652
To view Aquilon Pharma’s complete patent history, request access »

Aquilon Pharma Executive Team (10)

Name Title Board Seat Contact Info
Paul Maes Co-Founder, Chief Executive Officer & Chairman
Pascal Alexis Chief Financial Officer
Damien Thiéry Chief Operating Officer & Chief Corporate Development Officer
Didier Cataldo Co-Founder, Chairman of Scientific Committee, Administrator & Board Member
Brigitte Evrard Co-Founder
You’re viewing 5 of 10 executive team members. Get the full list »

Aquilon Pharma Board Members (4)

Name Representing Role Since
Didier Cataldo Aquilon Pharma Co-Founder, Chairman of Scientific Committee, Administrator & Board Member 000 0000
Frank Pieters Aquilon Pharma Executive Chairman 000 0000
Gauthier van der Elst Scale Investment Funds Board Member 000 0000
Paul Maes Aquilon Pharma Co-Founder, Chief Executive Officer & Chairman 000 0000
To view Aquilon Pharma’s complete board members history, request access »

Aquilon Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aquilon Pharma Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Noshaq Venture Capital Minority 000 0000 000000 0
SambrInvest Venture Capital Minority 000 0000 000000 0
Scale Investment Funds Venture Capital Minority 000 0000 000000 0
Be Angels Angel Group Minority 000 0000 000000 0
WBC Ventures Accelerator/Incubator 000 0000 000000 0
To view Aquilon Pharma’s complete investors history, request access »

Aquilon Pharma FAQs

  • When was Aquilon Pharma founded?

    Aquilon Pharma was founded in 2011.

  • Who is the founder of Aquilon Pharma?

    Paul Maes, Didier Cataldo, Brigitte Evrard, and François Boitquin are the founders of Aquilon Pharma.

  • Who is the CEO of Aquilon Pharma?

    Paul Maes is the CEO of Aquilon Pharma.

  • Where is Aquilon Pharma headquartered?

    Aquilon Pharma is headquartered in Liege, Belgium.

  • What is the size of Aquilon Pharma?

    Aquilon Pharma has 22 total employees.

  • What industry is Aquilon Pharma in?

    Aquilon Pharma’s primary industry is Pharmaceuticals.

  • Is Aquilon Pharma a private or public company?

    Aquilon Pharma is a Private company.

  • What is the current valuation of Aquilon Pharma?

    The current valuation of Aquilon Pharma is 00.000.

  • What is Aquilon Pharma’s current revenue?

    The current revenue for Aquilon Pharma is 000000.

  • How much funding has Aquilon Pharma raised over time?

    Aquilon Pharma has raised $9.5M.

  • Who are Aquilon Pharma’s investors?

    Noshaq, SambrInvest, Scale Investment Funds, Be Angels, and WBC Ventures have invested in Aquilon Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »